ACADIA Pharmaceuticals Inc (NAS:ACAD)
$ 16.95 -0.42 (-2.42%) Market Cap: 2.89 Bil Enterprise Value: 2.37 Bil PE Ratio: 22.27 PB Ratio: 5.01 GF Score: 75/100

ACADIA Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 08, 2021 / 06:10PM GMT
Release Date Price: $26.57 (+4.61%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good afternoon. Thanks for joining us. We're pleased to have the ACADIA team with us where we have Steve Davis, CEO; and Elena Ridloff, CFO.

With that, Steve, I'm going to turn it over to you for any opening comments, and then I'll get into questions.

Stephen R. Davis
ACADIA Pharmaceuticals Inc. - CEO & Director

Yes, that sounds great, Salveen. Thanks much, and I'll just start with a few level-setting brief comments, then we'll get right to the Q&A.

So I'll start just by highlighting the 3 pillars of our business. First pillar is we're driving NUPLAZID growth in Parkinson's disease psychosis. In the first quarter of 2021, we achieved net sales of $106.6 million. This represents an 18% year-over-year growth. We continue to add new prescribers and new patients and continue to also see very high adherence among our continuing PD psychosis patients. And although we experienced some COVID-related headwinds in the beginning of the year, as did, I think, the entire

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot